Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2014-001960-37 | EudraCT Number | EudraCT |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Effect of food on the pharmacokinetics of BI 1060469 (formulation tablet) in healthy male subjects as well as to investigate pharmacokinetics, safety and tolerability
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| BI 1060469 fed | Experimental | tablet, oral administration with 240 mL water 30 minutes after subject is served a standardised high-caloric high-fat administr |
|
| BI 1060469 fasted | Experimental | tablet, oral administration with 240 mL of water after an overnight fast of at least 10 h |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| BI 1060469 | Drug | tablet, oral administration with 240 mL of water after an overnight fast of at least 10 h |
|
| Measure | Description | Time Frame |
|---|---|---|
| AUC 0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point) | up to 6 days after last drug administration | |
| Cmax (maximum measured concentration of the analyte in plasma) | up to 6 days after last drug administration | |
| Frequency of subjects with drug-related adverse events | up to 7 days after last drug administration |
| Measure | Description | Time Frame |
|---|---|---|
| AUC0-infinity (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity) | up to 6 days after last drug administration |
Not provided
Inclusion criteria:
Exclusion criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Boehringer Ingelheim | Boehringer Ingelheim | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| 1333.44.1 Boehringer Ingelheim Investigational Site | Ingelheim | Germany |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| BI 1060469 | Drug | tablet, oral administration with 240 mL water 30 minutes after subject is served a standardised high-caloric high-fat administration |
|
| Other: standard breakfast | Drug | tablet, oral administration with 240 mL water 30 minutes after subject is served a standardised high-caloric high-fat administration |
|